- Home
- YQ vs RLYB Comparison
YQ vs RLYB Comparison
Compare YQ & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- RLYB
- Stock Information
- Founded
- YQ 2012
- RLYB 2018
- Country
- YQ China
- RLYB United States
- Employees
- YQ N/A
- RLYB N/A
- Industry
- YQ Other Consumer Services
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- RLYB Health Care
- Exchange
- YQ Nasdaq
- RLYB Nasdaq
- Market Cap
- YQ 19.4M
- RLYB 22.0M
- IPO Year
- YQ 2020
- RLYB 2021
- Fundamental
- Price
- YQ $1.97
- RLYB $0.63
- Analyst Decision
- YQ
- RLYB Hold
- Analyst Count
- YQ 0
- RLYB 3
- Target Price
- YQ N/A
- RLYB $15.00
- AVG Volume (30 Days)
- YQ 20.8K
- RLYB 458.7K
- Earning Date
- YQ 09-03-2025
- RLYB 08-07-2025
- Dividend Yield
- YQ N/A
- RLYB N/A
- EPS Growth
- YQ N/A
- RLYB N/A
- EPS
- YQ N/A
- RLYB N/A
- Revenue
- YQ $25,546,613.00
- RLYB $761,000.00
- Revenue This Year
- YQ N/A
- RLYB N/A
- Revenue Next Year
- YQ N/A
- RLYB N/A
- P/E Ratio
- YQ N/A
- RLYB N/A
- Revenue Growth
- YQ N/A
- RLYB 154.51
- 52 Week Low
- YQ $1.26
- RLYB $0.22
- 52 Week High
- YQ $3.19
- RLYB $1.25
- Technical
- Relative Strength Index (RSI)
- YQ 46.13
- RLYB 64.03
- Support Level
- YQ $1.94
- RLYB $0.53
- Resistance Level
- YQ $2.02
- RLYB $0.65
- Average True Range (ATR)
- YQ 0.07
- RLYB 0.06
- MACD
- YQ 0.01
- RLYB 0.00
- Stochastic Oscillator
- YQ 75.00
- RLYB 90.44
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.